Ocuphire Presenting New Data and Updates on APX3330 and Nyxol® Clinical Programs at Virtual Investor R&D Day

New data support Phase 3 development of Nyxol alone as a durable single eye drop for the potential treatment of Presbyopia First update on recruitment in APX3330 ZETA-1 Phase 2b trial: ~70% patients... | January 31, 2022

Related Keywords

,David Boyer ,James Katz ,Kols Jay Pepose ,Bindu Manne ,Mina Sooch ,Mitchell Jackson ,Peter Kaiser ,Kolspaul Karpecki ,Corey Davis ,Kols Mark Kelley ,Ocuphire Pharma ,Head Of Market Development ,Nasdaq ,Ocuphire Pharma Inc ,Investor Rd Day ,Key Opinion Leaders ,Diabetic Retinopathy ,Mark Kelley ,Paul Karpecki ,Market Development ,Jay Pepose ,New Drug Applications ,Anticipated Milestones ,Nyxol Phase ,Vision Disturbances ,Diabetic Macular Edema ,Private Securities Litigation Reform Act ,Nc Stock Exchange ,News ,Information ,Press Release ,Few ,Data ,Support ,Hase ,Development ,F ,Yxol ,Alone ,Us ,Durable ,Single ,Eye ,Drop ,Or ,The ,Potential ,Treatment ,Presbyopia ,First ,Update ,N ,Recruitment ,Px3330 ,B Ocup Us67577r1023 ,